A 'hypoxia in a pill' reversed Parkinson's symptoms — in mice

Edited by Samael A. Tejada, Founder & Editor-in-Chief

The idea sounds backwards: for a brain disease, give less oxygen. The logic is mitochondrial. In Parkinson's models, damaged mitochondria cannot consume oxygen efficiently, so delivery exceeds use — an oxygen mismatch that fuels damage. Breathing 11% oxygen helped Parkinson's-model mice in a 2025 study; the new work, published in PNAS and reported by ScienceAlert on October 22-23, 2026, asks whether two pills can do the same job.

What do the two drugs each do?

Hong Wang and colleagues in Mootha's lab used GBT601, a second-generation molecule that binds hemoglobin and increases its affinity for oxygen, so blood releases less oxygen into tissues. Because the body compensates by making more red blood cells, the second drug, PT2399, inhibits the HIF-2alpha pathway to limit that response. The Broad Institute notes both drug classes have been tolerated in safety studies in healthy human volunteers for other uses — which is not the same as being tested for Parkinson's.

What happened in the mouse models?

In the Parkinson's model, treated mice became quicker at descending a pole and could hold onto a cage lid for longer, with treatment starting after movement problems had already appeared — a reversal, not just prevention, in mice. In 50-day-old mice with advanced Leigh syndrome, a primary mitochondrial disease, the regimen extended expected lifespan from about 62 days to 158 days. The team also reported delayed progression in a Friedreich's ataxia mouse model.

Why should readers keep this in the 'mice' column?

Because every efficacy result here is in mice, the optimized combination has not been given to people with Parkinson's, Leigh syndrome or ataxia, and reducing oxygen delivery is inherently double-edged — the researchers themselves have warned against unsupervised low-oxygen exposure. Mootha's own framing is careful: the regimen merits further preclinical and eventually clinical testing. Anecdotes about Parkinson's symptoms improving at altitude are a hypothesis, not a recommendation to seek thin air.

Where the evidence stands

• Established: Mitochondrial dysfunction is central to Parkinson's disease and to Leigh syndrome and Friedreich's ataxia; in mouse models, continuously breathing 11% oxygen improved Parkinson's-like symptoms (2025).
• Preliminary: In mouse models (PNAS, reported Oct 22-23, 2026), GBT601 plus PT2399 reversed Parkinson's movement symptoms after onset, matched 11% oxygen breathing, extended Leigh syndrome mouse lifespan from ~62 to ~158 days, and delayed Friedreich's ataxia progression.
• Absent: Human efficacy or long-term safety data for this combination in any of these diseases, and any approved hypoxia-mimetic treatment for Parkinson's.